Journal article
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
SJ Harrison, H Quach, E Link, JF Seymour, DS Ritchie, S Ruell, J Dean, H Januszewicz, R Johnstone, P Neeson, M Dickinson, J Nichols, HM Prince
Blood | Published : 2011
Abstract
We report results from a study exploring the combination of romidepsin, bortezomib, and dexamethasone for the treatment of patients with multiple myeloma (MM) previously treated with > 1 prior therapy. The primary objective was to determine the maximum tolerated dose (MTD) of the combination using a novel accelerated dose-escalation schedule in patients with relapsed or refractory MM. The secondary objective was to determine overall response (OR), time to progression (TTP), and overall survival (OS). The MTD identified was bortezomib 1.3 mg/m2 (days 1, 4, 8, and 11), dexamethasone 20 mg (days 1, 2, 4, 5, 8, 9, 11, and 12), and romidepsin 10 mg/m2 (days 1, 8, and 15) every 28 days. Thrombocyt..
View full abstractGrants
Funding Acknowledgements
This was an investigator-initiated trial with financial support from Celgene (formerly Gloucester Pharmaceuticals). S.J.H. receives research support from the Vaccari Foundation. R.J. receives research support from the National Health and Medical Research Council of Australia, the Victorian Cancer Agency, and the Leukemia Foundation of Australia.J.N. is an employee of Celgene Corporation. S.J.H. and H. M. P. receive research funding from and have been members of advisory boards for Celgene Corporation and Janssen Cilag. J.F.S. and D. S. R. receive research funding from and have been members of advisory boards for Celgene Corporation. P.N. and H. Q. receive research funding from Celgene Corporation.